A study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals' herpes simplex candidate vaccine (gD2-ASO4) [herpes simplex glycoprotein vaccine] in healthy HSV seronegative and seropositive female subjects aged 10-17 years.

Trial Profile

A study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals' herpes simplex candidate vaccine (gD2-ASO4) [herpes simplex glycoprotein vaccine] in healthy HSV seronegative and seropositive female subjects aged 10-17 years.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs GSK 208141 (Primary) ; AS04A; Hepatitis A vaccine inactivated
  • Indications Hepatitis A
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 09 Oct 2008 Actual start date changed from April 2004 to November 2003, as reported by ClinicalTrials.gov. Actual patient number reported as 5960.
    • 28 Jan 2008 Status changed from in progress to completed; according to clinicaltrials.gov.
    • 02 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top